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Background
For the production of recombinant proteins, a human
cell-derived expression technology can offer significant
advantages with respect to protein quality, serum half-
life and safety. High volumetric productivity with first-
class quality is the ultimate ambition during process
development.
CEVEC’s proprietary expression system based on
human amniocytes offers significant advantages for the
production of complex human proteins and antibodies.
The key benefits are the stable and high expression of
recombinant proteins with human type posttranslational
modifications, the robust growth behaviour with compe-
titive high cell densities and the easy handling in serum
free suspension. CAP cells meet all regulatory require-
ments, they are of non-tumour origin and from an ethi-
cally accepted source.
In order to test the performance of CAP cells for the
production of very complex proteins, stable C1-inhibitor
expressing CAP cells were developed. C1-inhibitor is a
serine protease inhibitor (serpin) and one of the most
heavily glycosylated plasma proteins bearing numerous
complex N- and O-glycans.
Material and methods
Cells: CAP cells stably expressing C1-inhibitor
Base medium: Protein Expression medium PEM
(Gibco #12661013) containing 4mmol*L
-1 glutamine
(Invitrogen #25030024)
Supplements: Soy Peptone E110 (OrganoTechnie
#AI885), Glucose (Sigma #G8679), Valproic acid VPA
(Sigma #4543)
ELISA: In-house C1-inhibitor ELISA using serum
derived C1-inhibitor as standard
SDS-PAGE/Western Blot: In-house Western Blot for
C1-inhibitor
To investigate the influence of different hydrolysates
and supplements under controlled conditions we use
DASGIP´s parallel bioreactor system for cell culture. See
table 1 for standard physical process parameters.
Results
Parental CAP cells were transfected with a plasmid con-
taining expression cassettes for the human C1-inhibitor
driven by the CMV promoter, and a Blasticidine resis-
t a n c eg e n ef o rs e l e c t i o n .O u t of three stable pools, one
pool was selected for further single cell cloning by limit-
ing dilution. From initial 251 single cell clones, the best
5 were chosen for further scale-up. Subsequent process
development was carried out with one clone showing
the best performance in growth and expression.
First we tested the influence of different media supple-
ments shown before to improve cell growth and produc-
tivity in CAP cells. Either additional glucose, glutamine,
pyruvate, soy peptone, tryptone plus, tryptone or an in-
house mixture of R3-IGF, transferrin, SyntheChol and
progesterone were added to the base medium. Cells
were cultivated in shake flasks and cell densities, viabil-
ities, metabolites and product concentration were moni-
tored continuously.
Whereas the in-house mixture lead to higher growth
rates, the product yields increased upon the addition of
glucose (1.2-fold), soy peptone or tryptone (1.5-fold).
Based on these results, we tested additional hydroly-
sates from cotton seed, wheat gluten, rice protein and
soy. Hydrolysates and extra glucose were added to the
initial medium and cells were cultivated in shake flasks.
Only medium supplemented with soy peptone II (up
to 1.7-fold) and with cotton seed hydrolysate (up to 2.4-
fold) showed better performance as compared to the
control with extra glucose but without hydrolysate.
* Correspondence: essers@cevec.com
CEVEC Pharmaceuticals GmbH, Gottfried-Hagen-Str. 62, D-51105 Köln,
Germany
Essers et al. BMC Proceedings 2011, 5(Suppl 8):P66
http://www.biomedcentral.com/1753-6561/5/S8/P66
© 2011 Essers et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.In addition to medium supplementation we deter-
mined the optimal pH value for good growth rates, high
product quantity and quality. The different batches (pH
unregulated, pH 7.0, 7.2 or 7.4) did not differ in maxi-
mal product concentrations but in product qualities.
This was monitored with SDS-PAGE and western blot.
Due to additional specific bands at pH7.2 and pH7.4
either caused by degradation or incomplete glycosylation
we decided to continue with pH7.0 for following process
development steps.
Under controlled conditions additional glucose alone
or either with soy peptone I, soy peptone II or cotton
seed hydrolysate were supplemented to the base med-
ium. Parallel fermentations with different enriched
media were started at pH7.0 and cell densities of
3.0*10
5mL
-1 under controlled conditions. Cotton seed
hydrolysate increased growth, but highest cell density
could be observed with soy peptone II or without hydro-
lysate addition. The maximum product concentration
was higher compared to the control in all peptone-fed
fermentations. Supplementing soy peptone II or cotton
seed hydrolysate almost doubled maximum product
concentration.
As a next step, we examined the effect of valproic acid
(VPA) on productivity. VPA is a short-chain fatty acid
used as well established drug and classified histone dea-
c e t y l a s ei n h i b i t o r .W es e tu pt w oc u l t u r e sw i t hg l u c o s e
and soy peptone II and two cultures with glucose and
cotton seed hydrolysate. In each case, one of the dupli-
cate cultures was additionally supplemented with
4mmol*L
-1 VPA.
Initial cell densities were 3.5*10
5mL
-1 in all four paral-
lel controlled cultures. The addition of VPA was carried
o u ta tv i a b l ec e l ld e n s i t i e so f3 . 0 * 1 0
6mL
-1.A d d i t i o no f
VPA resulted in 1.6-2.0-fold increase in productivity
compared to the corresponding control cultures without
VPA
To determine the product quality we performed Wes-
tern blots with samples from the supernatant of the
batches supplemented with VPA. The highest protein
quality was obtained from the Soy peptone II-supple-
mented cultures.
We confirmed the results with 8 (parallel) runs and
observed consistent results for cell densities, growth
behaviour, product titers, cell specific and volumetric
productivities.
Conclusions
The optimized fed batch strategy starting with 2g*L
-1
extra glucose and 4g*L
-1 soy peptone II and addition of
4mmol*L
-1 VPA at a viable cell denstity of 3.5*10
6mL
-1
yields 4.3-fold higher volumetric productivity as
Table 1 Standard physical process parameters for
DASGIP fermentation
process parameter
T 37°C
V 0.6L
stirring marine impeller, 120rpm
aeration sparging, 0.03vvm
pH 7.0 (CO2/ 0.5M NaOH)
DO 40% (air saturation)
starting cell density 3-5E5mL
-1
Figure 1 Process development C1-inhibitor expressing CAP cell line – Improvement of volumetric productivity.
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mized fed batch we are able to produce 200-250 mg*L
-1
C1-inhibitor.
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